A 2025 study in JAMA Network Open found that people with type 2 diabetes who took semaglutide (Ozempic) or tirzepatide (Mounjaro) had a 76% higher risk of developing a rare condition called nonarteritic anterior ischemic optic neuropathy (NAION)
Blood 108 , 167176 (2006)
Explore Drug Addiction Treatment Centers Promising Data on GLP-1s for Addiction A 2024 review identified two randomized control trials that showed a significant effect of GLP-1RA on decreasing SUD. The details: One study pertained to alcohol, the other to nicotine In the alcohol study, participants drank 29% less compared to their baseline intake (Probst et al., 2023) dulaglutide once a week for 12 weeks A third study only showed SUD results (alcohol) for patients who were also obese (Klausen et al., 2022) In this study, one GLP-1 (Exenatide) decreased total intake and the number of heavy drinking days by almost 24% once a week for 26 weeks The 2024 review concludes that GLP-1s have a a potential role in SUD
Available from: 2 Knezevic NN, Mandalia S, Raasch J, Knezevic I, Candido KD
These products of GH action at the level of the liver form a ternary complex in circulation that influences the ability of IGF-1 to bind its peripheral insulin-like growth factor 1 receptor (IGF-1R)
